One Chain Immunotherapeutics

This week is #BrainTumourAwarenessWeek. #Glioblastoma remains one of the most aggressive and challenging primary brain tumours.

#OneChain and @VHIO are developing OC-4, a dual CAR-T therapy designed to address this complex and varable tumour.

More: lnkd.in/ePup9kf3

At #OneChain, our investigational CD1a-directed CAR-T cell therapy, OC-1, is being evaluated in the CARxALL first-in-human clinical trial for patients with relapsed or refractory T-cell acute lymphoblastic leukaemia/lymphoma (T-ALL/T-LL).

Learn more: lnkd.in/efnZzdhk

In November, #OneChain will be heading to #BIOEurope 2026, 9-11th November.

Our CEO, Stefanos Theoharis, with Barbara Krebs-Pohl, our Chair of the Board, will be at this year’s meeting to connect with investors and the global biotech and pharma community.

@EBDgroup

🔝 Next week, Víctor Manuel Díaz Cortés, Head of Research at #OneChain, will be presenting at the @festofbiologics:

“From Rational CAR Design to First-in-Human Translation: Expanding CAR-T to T-ALL and Beyond.”
🗓️13/10 at 17:10
📍Cell Therapy track

Come and join the session!

In Vivo CAR-T therapy has many benefits, this is why at OneChain, we’ve developed a next-generation lentiviral in vivo CAR-T platform.

Learn more about it in the infographic, or visit lnkd.in/d3DWa6fP

#CART #AdvancedTherapies #Biotech